Abstract
IntroductionMaintenance therapy with PARP inhibitors (PARPi) can increase progression free survival (PFS) in recurrent or metastatic platinum-sensitive epithelial ovarian cancer (EOC), though some evidence suggests a decreased response to subsequent...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
